Learning Center
Plans & pricing Sign in
Sign Out



									                        An ICON plc Company

                                                                                Late Phase & Outcomes Research

Speaker Profile
Two courses in Late Phase and Outcomes Research

Beth Woods
Director, Health Economics Team

MSc, Economic Evaluation in Health Care, City University, 2009
Dissertation “An iterative decision analytic modelling approach to the economic evaluation of pharmacogenetic testing in
early stage breast cancer”
BA Hons, Economics, Cambridge University, 2005
Dissertation “Can preference variation explain charitable contributions of time?”

At Oxford Outcomes
Beth is a Director of the Health Economics group in Oxford, which she originally joined in October 2006.
Beth has managed projects in breast cancer (early and metastatic), chronic lymphocytic leukaemia, relapsing remitting
multiple sclerosis, rheumatoid arthritis, malignant pleural mesothelioma, secondary progressive multiple sclerosis,
Hodgkin’s and non-Hodgkin’s lymphoma and heart failure.
This has included preparation of models and submission documentation to support reimbursement submissions to NICE
(MTA and STA submissions) and the SMC. She has conducted systematic reviews and led the programming of cost-
effectiveness models in these therapeutic areas. She also has experience of early stage modelling and strategic consulting
to support internal decision making including pricing and study design.
Beth’s methodological interests include all aspects of evidence synthesis and health technology appraisal of biomarker-
based treatment pathways.

Areas of expertise
Beth is an experienced modeller and has designed and executed decision tree, area under the curve, Markov and
patient level simulation models in a range of software packages. Her experience also includes designing and executing
analyses of individual patient data (in SAS and R) to inform decision models and conducting network meta-analysis (mixed
treatment comparisons) (WinBUGS and frequentist packages).
                        An ICON plc Company

                                                                                Late Phase & Outcomes Research

Speaker Profile
Two courses in Late Phase and Outcomes Research

Woods B, Veenstra D, Hawkins N. Prioritising pharmacogenetic research: A value of information analysis of CYP2D6
testing to guide breast cancer treatment. Value in Health forthcoming.
Woods B, Paracha N, Scott DA, Thatcher N. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus
cisplatin in patients with malignant pleural mesothelioma. Lung Cancer 2011 Sep 19. [Epub ahead of print]
Woods B, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, incorporating binary data and multi-arm
trials: a tutorial. BMC Medical Research Methodology 2010:10(54).
Hawkins N, Scott DA, Woods B. How far do you go? Efficient searching for indirect evidence. Medical Decision Making
2009; 29(3): 273-81.
Hawkins N, Scott DA, Woods B, Thatcher N. No study left behind: a network meta-analysis in non-small cell lung cancer
demonstrating the importance of considering all relevant data. Value in Health 2009; 12(6): 996-1003.
Conference proceedings
Woods B, Jensen J, Morris J, Punekar Y, Davies A, Hawkins N. Cost-effectiveness of biological therapy in the UK for
the treatment of rheumatoid arthritis following exposure to a previous tumour necrosis factor alpha inhibitor: a patient
level simulation model. Presented at the European League Against Rheumatism (EULAR) Annual European Congress of
Rheumatology. Rome, 16-19 June 2010. [Poster]
Woods B, Hawkins N. Use of pharmacogenetic testing to determine adjuvant hormonal therapy choice in early stage
breast cancer patients: a value of information analysis. Presented at the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) 14th Annual International Meeting. Florida, 16-20 May 2009. Value in Health 2009; 12(3):
A1-A203 (PM3). [Oral presentation]
Hawkins N, Scott D, Woods B, Thatcher N. Time to broaden our horizons: the case for network meta-analysis within
relapsed non-small cell lung cancer (NSCLC). Presented at the 33rd meeting of the European Society for Medical
Oncology (ESMO). Stockholm, 12-16 September 2008. [Poster]

To top